Latest Ventricular assist device Stories
FRAMINGHAM, Mass. and SYDNEY, May 16, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013. The conference is being held May 20-22, 2013 at the Sheraton New...
Dr. Jack Copeland Recognized for His Landmark Contributions in the Field of Heart Transplantation TUCSON, Ariz., May 16, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that world-renowned heart surgeon and SynCardia co-founder Jack G. Copeland, MD, was awarded the prestigious Pioneer in Transplantation Award at the annual meeting of the...
PLEASANTON, Calif., May 14, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Bank of America Merrill Lynch 2013 Health Care Conference on Thursday, May 16. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 10:40 a.m., Pacific Daylight Time (1:40 p.m.,...
FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013. The conference is being held...
- Revenue of $117.7 million for the first quarter of 2013 PLEASANTON, Calif., May 2, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the first quarter of 2013. For the quarter ended March 30, 2013, Thoratec reported revenues of $117.7 million, a 7 percent decrease versus revenues of $126.8 million in the same...
-- Phase II, randomized, placebo-controlled study at Glenfield Hospital, University of Leicester (UK) will measure primary efficacy endpoint of change from baseline in left ventricular ejection fraction (LVEF) post-percutaneous coronary intervention (PCI) -- TORONTO, May 2, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company's autoRIC(TM) Device for Chronic Remote Ischemic Conditioning...
TEL AVIV, Israel, May 2, 2013 /PRNewswire/ -- Leviticus Cardio [http://www.leviticus-cardio.com ], a portfolio company of the Mofet Venture Accelerator [http://www.mofet-venture.com ], owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75% full system efficiency rate as compared with...
PLEASANTON, Calif., April 22, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the first quarter of fiscal year 2013 on Thursday, May 2. The company will hold a conference call to discuss its financial results and operating activities, open to all interested parties, at 1:30 p.m., Pacific Daylight...
FRAMINGHAM, Mass. and SYDNEY, April 15, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2013, at 5:00 p.m. U.S. Eastern Daylight Time on Monday, April 29, 2013. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the first quarter...
ANN ARBOR, Mich., April 5, 2013 /PRNewswire/ -- Terumo Cardiovascular Systems today announced that it has entered into a multi-year distribution agreement with Nonin Medical, Inc., a leader in noninvasive medical monitoring. Beginning May 1, 2013, Terumo CVS will distribute Nonin's EQUANOX(TM) Model 7600 Regional Oximetry System to adult and pediatric cardiovascular hospitals in the United States; Nonin's direct sales force will focus on certain non-cardiovascular applications in...
Latest Ventricular assist device Reference Libraries
The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...
